Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results

Ophthalmology

Volumn 123, Issue 1, 2016, Pages 51-59

  Berg, Karina ^a   Hadzalic, Emina ^b   Gjertsen, Inger ^c   Forsaa, Vegard ^d   Berger, Lars Haakon ^e   Kinge, Bettina ^f   Henschien, Hans ^g   Fossen, Kristian ^h   Markovic, Slavica ⁱ   Pedersen, Terje R ^a   Sandvik, Leiv ^a   Bragadottir, Ragnheiur ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Betanien Hospital   (Norway)

^c VESTRE VIKEN HOSPITAL TRUST   (Norway)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e Østfold Hospital   (Norway)

^f Retina Clinic   (Norway)

^g VESTFOLD HOSPITAL TRUST   (Norway)

^h UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

ⁱ Innlandet Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

ADULT; AGE RELATED MACULAR DEGENERATION; CENTRAL RETINAL THICKNESS; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; VISUAL ACUITY; AGED; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MIDDLE AGED; RETINAL NEOVASCULARIZATION; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RANIBIZUMAB; RETINAL NEOVASCULARIZATION; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84951050380     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.09.018     Document Type: Conference Paper

References (19)

1. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012;153:209-13.
2. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
3. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration.NEngl J Med 2006;355:1432-44.
4. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
5. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN Study Investigators. Alternative treatments to inhibit VEGF in agerelated choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67.
6. Krebs I, Schmetterer L, Boltz A, et al; MANTA Research Group. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013;97:266-71.
7. Kodjikian L, Souied EH, Mimoun G, et al; GEFAL Study Group. Ranibizumab versus bevacizumab for neovascular agerelated macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013;120:2300-9.
8. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009;148:43-58.
9. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-24.
10. Schmidt-Erfurth U, Eldem B, Guymer R, et al; EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118:831-9.
11. Spaide R. Ranibizumab according to need: a treatment for agerelated macular degeneration. Am J Ophthalmol 2007;143: 679-80.
12. Engelbert M, Zweifel SA, Freund KB. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009;29:1424-31.
13. Engelbert M, Zweifel SA, Freund KB. Long-term followup for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy [erratum in Retina 2011;31:208]. Retina 2010;30:1368-75.
14. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134-40.
15. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011;31:26-30.
16. Abedi F, Wickremasinghe S, Islam AF, et al. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina 2014;34:1531-8.
17. Rayess N, Houston SK III, Gupta OP, et al. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 2015;159:3-8.
18. Toalster N, Russell M, Ng PA. 12-month prospective trial of inject and extend regimen for ranibizumab treatment of agerelated macular degeneration. Retina 2013;33:1351-8.
19. Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015;122:146-52.